News Releases

Vetter continues its long-term investment strategy to sustain future growth

Existing buildings are repurposed as others continue to be built and recently housed

Released by: Vetter Pharma International GmbH

Kohlberg and Mubadala sign a definitive agreement to acquire majority stake in PCI Pharma Services

PHILADELPHIA – August 24, 2020 – PCI Pharma Services (“PCI“), a leading pharmaceutical and biopharmaceutical global supply chain solutions provider, and portfolio company of Partners Group, announced today the signing of a…

Released by: PCI Pharma Services

A strong signal in turbulent times: Vetter achieves carbon dioxide-neutral levels

Contract Development and Manufacturing Organization further expands its commitment to climate protection

Released by: Vetter Pharma International GmbH

PCI Pharma Services Announces Global Expansion of Clinical Trial Services

PCI Broadens Global Clinical Supply-Chain Service Offerings Into Mainland Europe

Released by: PCI Pharma Services

Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers Form Collaboration

to Develop Emergent’s COVID-19 Hyperimmune Globulin (COVID-HIG) Product Candidate with U.S. Department of Defense Funding

Released by: Emergent BioSolutions, Inc.

Vetter further expands its Development Service with new site in Austria

With the new Vetter Development Service Rankweil site in Austria, Vetter expands its European footprint.

Released by: Vetter Pharma International GmbH

Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing

for Johnson & Johnson’s Lead COVID-19 Vaccine Candidate

Released by: Emergent BioSolutions, Inc.

The key to tackling drug development complexity: Collaboration.

Rentschler Biopharma and Vetter team up with joint goal to simplify processes and optimize time-to-market

Released by: Vetter Pharma International GmbH

Multimillion Dollar Investment Firmly Establishes Commercial Operations Globally to Support Business

PCI Pharma Services Announces Completion of Biotech Center of Excellence in Philadelphia and Expansions to Biotech Capabilities in Europe

Released by: PCI Pharma Services

Emergent BioSolutions to Invest $75 Million

in Canton Site and Expand Viral Vector and Gene Therapy Capability

Released by: Emergent BioSolutions, Inc.

Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner

for AstraZeneca’s COVID-19 Vaccine Candidate

Released by: Emergent BioSolutions, Inc.

Flow Sciences, Inc. Supplies 10 Enclosures for High Capacity COVID-19 Testing

Personnel protection was required while processing virus samples

Released by: Flow Sciences, Inc.

Toronto centre solving cell manufacturing challenges to benefit patients and global industry

CCRM and Cytiva, formerly part of GE Healthcare Life Sciences, renew collaboration agreement for Centre for Advanced Therapeutic Cell Technologies

Released by: CCRM

Emergent BioSolutions Joins U.S. Government’s Warp Speed Program

in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and Manufacturing

Released by: Emergent BioSolutions, Inc.

Vetter wins Axia Best Managed Companies Award

Seal of quality for outstanding corporate management Analysis of the areas of strategy, innovation, corporate culture and finance Comprehensive three-stage application process Ravensburg, Germany, May 28, 2020 &nda…

Released by: Vetter Pharma International GmbH